RT Journal Article
SR Electronic
T1 Anticoagulation in special patient populations
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP S37
OP S42
VO 72
IS 4 suppl 1
A1 Michota, Franklin
A1 Merli, Geno
YR 2005
UL http://www.ccjm.org/content/72/4_suppl_1/S37.abstract
AB Optimal dosing of low-molecular-weight heparin (LMWH) therapy has not yet been established for patients with morbid obesity or renal insufficiency or for pregnant women. Monitoring of anti-Xa levels appears to be helpful in guiding LMWH dosing in all of these patient groups. Use of fondaparinux in these populations has yet to be defined. Cancer patients are at particular risk of venous thromboembolism and generally require escalated and/or prolonged anticoagulation with intense monitoring of therapy.